BCRX: BioCryst Pharmaceuticals Inc

8.22 USD 0.03 (0.36%)

版块: 医疗保健基础: US Dollar 盈利货币: US Dollar

今日BCRX汇率已更改-0.36%。当日，交易品种以低点8.12和高点8.39进行交易。

关注BioCryst Pharmaceuticals Inc动态。实时报价将帮助您快速应对市场变化。通过在不同的时间周期之间切换，您可以按分钟、小时、天、周和月监控汇率趋势和动态。使用这些信息来预测市场变化并做出明智的交易决策。

全屏图表

BCRX新闻

Zacks 14:00 Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
Zacks 14:00 BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth
Investing 17:32 BioCryst stock undervalued ahead of Q2 earnings, says RBC Capital
Investing 17:20 Citizens JMP downgrades Clearside Biomedical stock rating as company pauses R&D
Investing 11:46 Clearside Biomedical stock falls after announcing strategic alternatives exploration
Seeking Alpha 19:24 Astria: Betting On Navenibart In The Crowded HAE Arena
Investing 11:05 BioCryst Pharmaceuticals appoints Babar Ghias as CFO
Benzinga 14:41 BioCryst Just Ditched Its Europe Business — Here's Why Investors Are Cheering - BioCryst Pharma (NASDAQ:BCRX)
Investing 12:19 BioCryst stock rises after $264 million sale of European ORLADEYO business
Investing 11:04 BioCryst to sell European ORLADEYO business to Neopharmed for $264M
Investing 11:04 FDA extends review period for BioCryst pediatric drug application to December
Investing 11:09 BioCryst reports long-term efficacy of ORLADEYO in HAE treatment
Investing 11:06 Colombia approves BioCryst’s oral HAE treatment ORLADEYO
Investing 14:15 BioCryst at Goldman Sachs Conference: Strategic Growth and Profitability
Seeking Alpha 21:26 Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside
Investing 11:05 Netherlands approves BioCryst’s HAE drug ORLADEYO for reimbursement
Investing 11:36 biocryst pharmaceuticals extends cfo consulting agreement
Investing 11:32 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Investing 11:32 BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
Investing 11:06 BioCryst reports efficacy of HAE drug across age groups
Investing 13:44 Cantor Fitzgerald maintains overweight on Metsera shares
Investing 11:28 BioCryst to Present at Upcoming Investor Conferences
Investing 11:05 BioCryst reports ORLADEYO reduces severe HAE attack rates
Benzinga 21:29 BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors - BioCryst Pharma (NASDAQ:BCRX)

日范围

8.12 8.39

年范围

6.01 11.31

前一天收盘价: 8.09
开盘价: 8.25

卖价: 8.22
买价: 8.52

最低价: 8.12
最高价: 8.39

交易量: 5.803 K

日变化: -0.36%
月变化: -8.46%

6个月变化: 6.48%
年变化: 12.60%

30 七月, 星期三